Phase II Study of Cixutumumab in Combination with Temsirolimus in Pediatric Patients and Young Adults with Recurrent or Refractory Sarcoma: A Report from the Children’s Oncology Group

BACKGROUND: The combined inhibition of insulin-growth factor type 1 receptor (IGF-1R) and the mammalian target of rapamycin (mTOR) has shown activity in preclinical models of pediatric sarcoma and in adult sarcoma patients. We evaluated the activity of the anti-IGF-1R antibody cixutumumab with the m...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pediatr Blood Cancer
Main Authors: Wagner, Lars M., Fouladi, Maryam, Ahmed, Atif, Krailo, Mark D., Weigel, Brenda, DuBois, Steven G., Doyle, L. Austin, Chen, Helen, Blaney, Susan M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4501773/
https://ncbi.nlm.nih.gov/pubmed/25446280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25334
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados